The incidence of HPV-related oropharyngeal cancers has increased in recent decades. While cure rates exceed those of HPV-negative head and neck cancers, both acute and long-term sequelae of chemotherapy, radiation and surgery have led to clinical investigation into de-escalation of treatment. De-escalation trials have sought to reduce long-term treatment-related morbidity by altering or omitting chemotherapy, reducing radiation, or incorporating less invasive surgical resection through transoral surgery. More recent approaches include the use of novel agents such as immunotherapy in place of cisplatin. With the advent of tumor-tissue-modified HPV DNA detection and monitoring in blood, new strategies incorporating this biomarker are being developed.
近年来，人乳头瘤病毒相关口咽癌的发病率呈上升趋势。尽管其治愈率高于HPV阴性头颈癌，但化疗、放疗及手术引发的急性与长期后遗症促使临床界探索降阶梯治疗方案。当前降阶梯试验主要通过以下途径降低长期治疗相关并发症：调整或省略化疗方案、减少放疗剂量，或采用经口手术等微创切除技术。最新研究方向包括使用免疫疗法等新型药物替代顺铂治疗。随着肿瘤组织修饰HPV DNA血液检测与监测技术的出现，整合该生物标志物的新型诊疗策略正在不断发展。
肿瘤(癌症)患者之家